Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin- releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) Significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.
Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass / Lupoli, G.; Oi Carlo, C.; Nuzzo, V.; Vitale, G.; Russo, O.; Palomba, S.; Nappi, C.. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - (1997).
Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass
S. Palomba;
1997
Abstract
Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin- releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) Significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
